NPS Pharmaceuticals To Report Second Quarter 2013 Financial Results

NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its second quarter 2013 financial results on Thursday, August 8, 2013 at approximately 4:30 p.m. ET. The press release will be followed by a conference call and webcast at 5:00 p.m. ET.

To participate in the conference call, dial (866) 515-2910 and use passcode 33048269. International callers may dial (617) 399-5124, using the same passcode. In addition, a live audio of the conference call will be available over the Internet. Interested parties can access the event through the investors’ calendar of events page on the NPS website at http://www.npsp.com/calendar.

If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 43569894 until midnight ET, August 22, 2013. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available through the NPS website for the same period.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (teduglutide [rDNA origin]) for injection is approved in the U.S. for adult Short Bowel Syndrome (SBS) patients who are dependent on parenteral support. Teduglutide is also approved for adult SBS in the European Union under the brand name Revestive®. NPS also developed Natpara® (recombinant full-length human parathyroid hormone or rhPTH [1-84]) for the treatment of adult hypoparathyroidism and, subject to the resolution of certain manufacturing issues, expects to submit its Biologic License Application (BLA) to the FDA in 2013. NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals and Kyowa Hakko Kirin. Additional information about NPS is available through its corporate website, http://www.npsp.com.

Copyright Business Wire 2010

If you liked this article you might like

Mylan Bids $29 Billion for Perrigo in Latest Big Pharma Deal

Biotech Stocks Are Selling Off Just Like 2014 -- and That Might Be a Good Thing

Valeant Boosts Offer for Salix to $15.8 Billion, Endo Drops Bid

'Mad Money' Lightning Round: Ambarella Is Like Putting a Gun to Your Head

Jim Cramer's 'Mad Money' Recap: Zombie Stocks That Will Rise From the Dead